ADC Therapeutics S.A.

NYSE:ADCT

Biotechnology

Healthcare
$1.37 -1.35%

-$0.02 today

Market cap
$192.71M
Beta
1.77
P/E (TTM)
-1.2
EPS (TTM)
-$0.89
52W Low $0.78High $4.98

Volume 1.17M

Average 1.68M

ADCT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

ADC Therapeutics S.A.NYSE: ADCT

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin narrows to 82.7%

Gross margin was 82.7% in Q1 FY2026, down 8.4 pp from a year earlier. On a trailing-twelve-month basis it was 90.7%, down 2.0 pp year over year. Over 3 fiscal years it narrowed by 7.9 pp.

Context

  • Gross margin widened in 0 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
82.7%-10.0 pp QoQ
Last fiscal yearDec 2025
90.6%-1.0 pp YoY
LTMMar 2026
90.7%-2.0 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-8.4 pp——
1 year-1.0 pp——
3 years-7.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
90.6%
Year-over-year change
-1.0pp

Gross Margin vs competitors

How ADCT compares with its peers on the latest reported figures

  • ADCT's LTM Mar 2026 gross margin of 90.7% is the 3rd highest of the 9 companies compared; the peer median is 14.4%.
  • Its year-over-year change of -2.0 pp is the 6th highest of 8, against a peer median of +83.0 pp.
  • Over three fiscal years its change of -7.9 pp compares with a peer median of +0.0 pp.
ADCT Competitors Peer median
Gross Margin for ADCT and competitors
Company Period LTM level YoY 3-year change
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 202699.1% +83.0 pp+37780.7 pp
LCTXLineage Cell Therapeutics, Inc.LTM Mar 202698.0% +0.8 pp-0.9 pp
ADCTADC Therapeutics S.A.LTM Mar 202690.7% -2.0 pp-7.9 pp
ALMSAlumis Inc. Common StockLTM Jun 202688.2% -7.7 pp—
QSIQuantum-Si incorporatedLTM Mar 202640.0% -12.8 pp—
AUTLAutolus Therapeutics plcLTM Mar 2026-11.2% +1636.4 pp-127.8 pp
BCYCBicycle Therapeutics plcLTM Mar 2026-11.9% +506.2 pp+0.0 pp
OMEROmeros CorporationLTM Mar 2026-12.4% ——
FDMT4D Molecular Therapeutics, Inc.LTM Mar 2026-12.4% +490439.7 pp+2555.9 pp
NMRANeumora Therapeutics, Inc. Common StockFY2025— ——
Peer median (excluding ADCT) 14.4%+83.0 pp+0.0 pp

Competitors are the stored peer set for ADCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue33.92M209.91M69.56M70.84M81.36M
Cost of Revenue1.39M3.3M2.53M5.95M7.67M
Gross Profit32.52M206.61M67.03M64.89M73.68M
Gross Margin95.9%98.4%96.4%91.6%90.6%
Research & Development158M186.46M127.13M109.63M104.01M
Selling, General & Admin136.24M143.49M105.89M85.91M(6.82M)
Operating Expenses294.24M329.95M233.02M195.54M182.06M
Depreciation & Amortization2.63M2.39M3.27M3.28M1.88M
EBITDA(230.54M)(107.7M)(145.83M)(102.65M)(89.27M)
EBITDA Margin-679.7%-51.3%-209.6%-144.9%-109.7%
Operating Income(261.72M)(123.34M)(165.99M)(130.65M)(108.38M)
Operating Margin-771.6%-58.8%-238.6%-184.4%-133.2%
Interest Income66K2.57M10.54M12.27M8.81M
Interest Expense18.34M36.73M46.33M50.21M51.63M
Other Income / Expenses10.22M(33.56M)(34.96M)(27.03M)(34.4M)
Income Before Tax(251.51M)(156.9M)(200.95M)(157.68M)(142.78M)
Pre-Tax Margin-741.5%-74.7%-288.9%-222.6%-175.5%
Income Tax Expense(21.48M)227K39.11M166K(157K)
Net Income(230.03M)(157.13M)(240.05M)(157.85M)(142.62M)
Net Margin-678.2%-74.9%-345.1%-222.8%-175.3%
EPS (Basic)(3.00)(1.99)(2.94)(1.62)(1.12)
EPS (Diluted)(3.00)(1.99)(2.94)(1.62)(1.12)
Weighted Avg Shares76.75M78.15M81.71M97.16M127.07M
Weighted Avg Shares (Diluted)76.75M78.15M81.71M97.16M127.07M

ADC Therapeutics S.A.

NYSE:ADCT

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.